HR
ATRC icon

Howe & Rusling’s AtriCure ATRC Stock Holding History

Howe & Rusling’s Portfolio ATRC Stock Details ATRC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-51
Closed -$2K – 929
2020
Q3 		$2K Hold
51
– – ﹤0.01% 687
2020
Q2 		$2K Buy
+51
New +$2.22K ﹤0.01% 655

Other funds holding ATRC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Howe & Rusling's ATRC Position: Q4 2020 in Review

Howe & Rusling sold out of AtriCure (ATRC) in Q4 2020, closing a stake of 51 shares — an estimated $2K sold.

Howe & Rusling first reported a position in ATRC in Q2 2020 and held it in 2 quarters. The position peaked at $2K in Q3 2020. 198 funds tracked by Wall St. Rank hold ATRC as of Q4 2020.

  • Howe & Rusling reported no remaining AtriCure position as of Q4 2020 after selling out during the quarter.
  • Howe & Rusling sold 51 AtriCure shares in Q4 2020, an estimated $2K.
  • Howe & Rusling first reported a position in AtriCure in Q2 2020 and held it in 2 quarters.
  • Howe & Rusling's AtriCure position peaked at $2K in Q3 2020.
  • 198 funds tracked by Wall St. Rank held AtriCure as of Q4 2020.

Based on Howe & Rusling's 13F filing for Q4 2020, filed 8 Feb 2021.